Drug intelligence / Profile preview

MT961

Development stage: Preclinical
Lead developer: Medytox
Administration: Oral

Overview

MT961 is a health supplement candidate currently in the discovery stage of development by Medytox. It is being investigated for its potential application in weight management and the treatment of obesity. As a functional food or nutraceutical product, MT961 represents Medytox's strategic diversification beyond its core botulinum toxin business into the metabolic health and wellness sector. Specific details regarding its active ingredients or precise mechanism of action have not been publicly disclosed, but it is positioned as a metabolic health product within the company's health functional food pipeline.

Beyond the preview

Go deeper on MT961.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT961.

Explore the full profile